Plain-English translation of NCT07430956 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing two experimental medications called and to see if they can prevent blood clots and strokes in people with atrial fibrillation (an irregular heartbeat) who cannot take standard blood thinners. These medications work by targeting a specific part of your blood's clotting system. About 2,600 people will participate to see how safe and effective this treatment is.
People with irregular heartbeats are at high risk for dangerous blood clots and strokes, but standard blood thinners don't work for everyone—some people have bleeding risks that make them unsafe. This study aims to find a new treatment option for patients in this situation.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either one of the two experimental medications or a placebo (a dummy treatment) and take it regularly as directed. The study will involve multiple visits to a research clinic where your blood will be tested, your heart will be monitored, and you'll be asked about any side effects or health changes. The study will track you over time to see how well the medication works at preventing strokes and blood clots compared to placebo.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States